

For immediate release

29 July 2024



**ALLIANCE PHARMA PLC**  
("Alliance" or the "Company")

**Result of AGM**

**Alliance Pharma plc** (AIM: APH), the international healthcare group, announces that, at its Annual General Meeting held earlier today, all the resolutions except resolutions 16 and 17, as set out in the Notice of Meeting, were duly passed on a poll.

The number of the Group's shares in issue as at the date of the meeting was 540,565,539 ordinary shares of 1p each\*.

The votes were as follows:

RESOLUTION	VOTES FOR	%	VOTES AGAINST	%	VOTES WITHHELD
1 Report and Accounts	190,733,158	99.99	14,451	0.01	12,870
2 Approve Remuneration Report	118,424,151	62.09	72,319,389	37.91	16,939
3 Elect C. Pane	167,821,883	99.34	1,108,987	0.66	21,829,609
4 Elect R. McKenzie	190,719,135	99.98	28,979	0.02	12,365
5 Elect EL Sjustedt	190,672,019	99.96	76,095	0.040	12,365
6 Elect N. Sedgwick	190,708,640	99.98	38,979	0.020	12,860
7 Re-elect A. Franklin	190,546,663	99.89	201,451	0.11	12,365
8 Re-elect J. Heper (Withdrawn)	-	-	-	-	-
9 Re-elect R. Jones	119,208,411	62.55	71,381,969	37.45	170,099
10 Re-elect K. Neiryndk	190,554,413	99.98	36,462	0.02	169,604
11 Re-elect M. Sutherland	119,879,952	62.90	70,710,923	37.10	169,604
12 Appointment of Auditor	190,656,799	99.95	90,085	0.05	13,595
13 Remuneration of Auditor	190,715,105	99.98	32,274	0.02	13,100
14 Allot shares - general	119,812,913	62.81	70,933,841	37.19	13,725
15 Allot shares - additional	120,008,767	62.92	70,735,963	37.08	15,749
16 Disapply pre-emption rights - general	119,970,667	62.90	70,776,712	37.10	13,100
17 Disapply pre-emption rights - additional	119,912,206	62.86	70,835,173	37.14	13,100

The Board notes the votes against Resolutions 2, 9, 11, 14, 15, 16 and 17 and will consult with shareholders to understand their views and publish the results of that consultation in due course.

Chris Chrysanthou  
Group General Counsel & Company Secretary  
29 July 2024

*\*Each share carries one vote and a 'vote withheld' is not a vote in law and has not been counted in the calculation of the proportion of the votes for and against the resolution. Any proxy appointments which gave discretion to the Chairman have been included in the 'votes for' total.*

**For further information:**

**Alliance Pharma plc**  
Cora McCallum, Head of Investor Relations & Corporate Communications  
[ir@allianceph.com](mailto:ir@allianceph.com)

**Buchanan**

**+ 44 (0)1249 466966**  
**+ 44 (0)1249 705168**

**+ 44 (0)20 7466 5000**

Mark Court / Sophie Wills  
[alliancepharma@buchanan.uk.com](mailto:alliancepharma@buchanan.uk.com)

**Deutsche Numis (Nominated Adviser and Joint Broker)**  
Freddie Barnfield / Duncan Monteith / Sher Shah

+ 44 (0)20 7260 1000

**Investec Bank plc (Joint Broker)**  
Patrick Robb / Ben Lawrence / Maria Gomez de Olea

+ 44 (0)20 7597 5970

## About Alliance

Alliance Pharma plc (AIM: APH) is a growing consumer healthcare company. Our purpose is to empower people to make a positive difference to their health and wellbeing by making our trusted and proven brands available around the world.

We deliver organic growth through investing in our priority brands and channels, in related innovation, and through selective geographic expansion to increase the reach of our brands. Periodically, we may look to enhance our organic growth through selective, complementary acquisitions.

Headquartered in the UK, the Group employs around 290 people based in locations across Europe, North America, and the Asia Pacific region. By outsourcing our manufacturing and logistics we remain asset-light and focused on maximising the value we can bring, both to our stakeholders and to our brands.

For more information on Alliance, please visit our website: [www.alliancepharmaceuticals.com](http://www.alliancepharmaceuticals.com)

This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact [ms@seg.com](mailto:ms@seg.com) or visit [www.ms.com](http://www.ms.com).

RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our [Privacy Policy](#).

END

RAGSESFIULSEFW